A November 2024 study by Tucker published in The New England Journal of Medicine demonstrates that weekly Tirzepatide (Mounjaro/Zepbound) can dramatically reduce the risk of progressing from prediabetes to type 2 diabetes, while also sustaining significant weight loss over three years. However, the study notes that some benefits were reversed after discontinuing the medication, underscoring the importance of continued treatment for lasting effects.
Comments